For example, the first GSP was enriched for tumor suppressors (eg, the targets of PRC2 component EED given that PRC2 has been previously reported to repress tumor suppressors [17]) whereas the second GSP was enriched for targets of oncogenes (such as FGFR1, MYCN, genes in the neurite outgrowth pathway, and common cancer module #1 [25]). The gene discussed is MYCN; the disease is cancer.